Drug Trial Radar · NCT01466153
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 20, 2026Latest source record: May 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Feb 7, 2012
Primary completion
Jan 8, 2016
Study completion Jan 8, 2016
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.
Conditions
- Chronic Lymphocytic Leukemia (CLL)
Interventions
RituximabDrug
Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
BendamustineDrug
Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
MEDI-551Drug
MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: From treatment administration (Day 1) until disease progression, death, initiation of alternative therapy, withdrawal of consent, or end of study (up to 24 months)
Locations
54 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Burbank, California
Research Site
La Jolla, California
Research Site
Palm Springs, California
Research Site
Skokie, Illinois
Research Site
Shreveport, Louisiana
Research Site
Baltimore, Maryland
Research Site
Detroit, Michigan
Research Site
Fargo, North Dakota
Research Site
Dayton, Ohio
Research Site
Newark, Ohio
Research Site
Watertown, South Dakota
Research Site
Lubbock, Texas
Research Site
Morgantown, West Virginia
Research Site
Antwerp, Belgium
Research Site
Arlon, Belgium
Research Site
Kortrijk, Belgium
Research Site
Mons, Belgium
Research Site
Wilrijk, Belgium
Research Site
Yvoir, Belgium
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Amiens, France
Research Site
Bayonne, France
Research Site
Bordeaux, France
Research Site
Le Mans, France
Research Site
Libourne, France
Research Site
Marseille, France
Research Site
Nîmes, France
Research Site
Dortmund, Germany
Research Site
Essen, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
München, Germany
Research Site
Würzburg, Germany
Research Site
Haifa, Israel
Research Site
Ramat Gan, Israel
Research Site
Bari, Italy
Research Site
Lecce, Italy
Research Site
Meldola, Italy
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.